Development overview

ReNeuron is using human somatic stem cells to develop cell transplantation treatments for a number of major neurodegenerative and other diseases. ReNeuron has also leveraged its stem cell technologies into non-therapeutic areas – its ReNcellTM range of cell lines for use in research and in drug discovery applications in the pharmaceutical industry.

Therapeutic programmes

ReNeuron has stem cell therapy programmes targeting the following diseases:

  • Stroke
  • Type 1 diabetes
  • Retinal diseases, such as age-related macular degeneration and retinitis pigmentosa
  • Parkinson's disease
  • Huntington's disease
The Company has targeted its principal cell therapy programmes at diseases where there is an unmet medical need and where there are substantial treatable patient populations.

Click on the programme headings on the chart to learn more about each programme.

ProgrammeResearchPre-clinical developmentClinical development
Stroke
(ReN001)

 

 

 

Type 1 diabetes
(ReN002)

 

 

 

Retinal diseases
(ReN003)

 

 

 

Parkinson's disease
(ReN004)

 

 

 

Huntington’s disease
(ReN005)

 

 

 

   

Non-therapeutic programmes - ReNCellTM

ReNeuron has developed and is marketing two of its neural stem cell lines, ReNcell VM and ReNcell CX, as assay tools in drug discovery. These cell lines display unique characteristics, giving them a competitive edge when compared with other cell lines typically used in drug discovery applications.

ReNeuron is also developing human hepatocyte (liver) cell lines for potential use as a toxicity screening tool.

Find out more about ReNeuron's ReNcell programmes.

Top of pageTop of page

See News for announcements regarding progress with our cell therapy and other programmes. You can also register for news update alerts.